formulation and evaluation of mouth dissolving tablets
... Amritsar (Punjab), India. *e-mail:neenagndu@yahoo.com ...
... Amritsar (Punjab), India. *e-mail:neenagndu@yahoo.com ...
incorporation of anti-cancer drug on mesoporous silica
... was placed under constant stirring for 30 min and then warmed up to 80 °C. Upon reaching the desired temperature, to this mixture was added 1.34 mL of tetraethoxysilane TEOS (Sigma Aldrich 98%). The mixture was left under stirring for 2 hours, maintaining the temperature of 80 °C. After this time, ...
... was placed under constant stirring for 30 min and then warmed up to 80 °C. Upon reaching the desired temperature, to this mixture was added 1.34 mL of tetraethoxysilane TEOS (Sigma Aldrich 98%). The mixture was left under stirring for 2 hours, maintaining the temperature of 80 °C. After this time, ...
02/12/14 - Magellan Rx Management
... Manual Review PA will be required for all requests for Procysbi® capsules and will be reviewed on a case-by-case basis. In addition, there will be a dose-optimization edit placed on the 25 mg strength that will allow up to a maximum of 4 capsules daily and a cumulative quantity edit of 124 per 31-da ...
... Manual Review PA will be required for all requests for Procysbi® capsules and will be reviewed on a case-by-case basis. In addition, there will be a dose-optimization edit placed on the 25 mg strength that will allow up to a maximum of 4 capsules daily and a cumulative quantity edit of 124 per 31-da ...
Prescription Drug Cost Sharing - Associations With Medication and
... reached, coverage resumes with minimal cost sharing. Prior to the introduction of Part D, benefit caps—without this catastrophic limit—were a standard feature of Medicare⫹Choice plans (now known as Medicare Advantage) and some retiree plans. As of 2002, 94% of Medicare ⫹ Choice plans that covered br ...
... reached, coverage resumes with minimal cost sharing. Prior to the introduction of Part D, benefit caps—without this catastrophic limit—were a standard feature of Medicare⫹Choice plans (now known as Medicare Advantage) and some retiree plans. As of 2002, 94% of Medicare ⫹ Choice plans that covered br ...
Quantitative Rationalization of Gemfibrozil Drug Interactions
... Subsequently, several studies were conducted to understand the mechanisms involved, and it was determined that gemfibrozil (twice a day for 5 days) increases cerivastatin oral AUC about 5-fold, which however was not assumed from the interaction potency of gemfibrozil alone (Backman et al., 2002). Si ...
... Subsequently, several studies were conducted to understand the mechanisms involved, and it was determined that gemfibrozil (twice a day for 5 days) increases cerivastatin oral AUC about 5-fold, which however was not assumed from the interaction potency of gemfibrozil alone (Backman et al., 2002). Si ...
(1151) pharmaceutical dosage forms
... such capsules may be printed axially or radially with strengths, product codes, etc. Pharmaceutical-grade printing inks are usually based on shellac and employ FDA-approved pigments and lake dyes. In extemporaneous prescription practice, hard-shell capsules may be hand-filled; this permits the prescr ...
... such capsules may be printed axially or radially with strengths, product codes, etc. Pharmaceutical-grade printing inks are usually based on shellac and employ FDA-approved pigments and lake dyes. In extemporaneous prescription practice, hard-shell capsules may be hand-filled; this permits the prescr ...
Polypharmacy, Adverse Drug Reactions, and Geriatric
... and decreased nutritional status, which may affect the pharmacokinetic and pharmacodynamic properties of medications.32 Potential drug-drug interactions are common. In a prospective, randomized controlled longitudinal multicenter European study of 1601 community-dwelling elderly adults, 46% of patie ...
... and decreased nutritional status, which may affect the pharmacokinetic and pharmacodynamic properties of medications.32 Potential drug-drug interactions are common. In a prospective, randomized controlled longitudinal multicenter European study of 1601 community-dwelling elderly adults, 46% of patie ...
AP-ZP - Edison Investment Research
... definitive benefit over other controlled release (CR) formulations. The company has MRI evidence that APs are effectively retained in the stomach, but the question remains how this translates into a benefit for any given compound. The advantages of the formulation are most well-established for AP-CD ...
... definitive benefit over other controlled release (CR) formulations. The company has MRI evidence that APs are effectively retained in the stomach, but the question remains how this translates into a benefit for any given compound. The advantages of the formulation are most well-established for AP-CD ...
Quantitative Structure-Activity Relationship Modeling to Predict Drug-Drug Interactions
... and cancer patient groups specifically, are at a higher risk from DDIs because they are administered multiple medications. Identifying DDIs early in the drug discovery and development process can reduce the number of hospitalizations due to drug interactions and allow more beneficial drugs to reach ...
... and cancer patient groups specifically, are at a higher risk from DDIs because they are administered multiple medications. Identifying DDIs early in the drug discovery and development process can reduce the number of hospitalizations due to drug interactions and allow more beneficial drugs to reach ...
< . 4- c
... Under 21 U.S. C. 350b(a), the manufacturer or distributor of a dietary supplement that contains a new dietary ingredient that has not been present in the food supply as an article used for food in a form in which the food has not been chemically altered must submit to FDA, at least 75 days before th ...
... Under 21 U.S. C. 350b(a), the manufacturer or distributor of a dietary supplement that contains a new dietary ingredient that has not been present in the food supply as an article used for food in a form in which the food has not been chemically altered must submit to FDA, at least 75 days before th ...
Fabrication and Evaluation of Curcumin-loaded
... longa ). It is a common ingredient in all forms of Indian diet, an effective agent to reduce the development of tumor and full of antioxidant, anti-inflammatory and anti-carcinogenic properties. It inhibits cancer in various tissues, including skin, mammary gland, oral cavity, forestomach, oesophagu ...
... longa ). It is a common ingredient in all forms of Indian diet, an effective agent to reduce the development of tumor and full of antioxidant, anti-inflammatory and anti-carcinogenic properties. It inhibits cancer in various tissues, including skin, mammary gland, oral cavity, forestomach, oesophagu ...
Journal Club Seminar
... absorption, and minimize local irritation of the mucosa by certain irritant drugs. Improved flow characteristics: Spheres have excellent flow properties which can be used in automated processes or in processes where exact dosing is required, e.g. tabletting, moulding operations, capsule filling, and ...
... absorption, and minimize local irritation of the mucosa by certain irritant drugs. Improved flow characteristics: Spheres have excellent flow properties which can be used in automated processes or in processes where exact dosing is required, e.g. tabletting, moulding operations, capsule filling, and ...
Lymphatic transport of orally administered drugs
... intestinal lymphatic delivery is to possess high log P (log partition coefficient) values above 5 (which implies about 50,000times greater affinity for lymph lipid than the portal blood) and good solubility (greater than 50mg/ml) in triglycerides (for better association during re-esterification in t ...
... intestinal lymphatic delivery is to possess high log P (log partition coefficient) values above 5 (which implies about 50,000times greater affinity for lymph lipid than the portal blood) and good solubility (greater than 50mg/ml) in triglycerides (for better association during re-esterification in t ...
Understanding Physicochemical Properties for
... The distribution/partition phenomenon is common and has been utilized to a great extent by various industrial and laboratory extraction processes. Organic compounds can be readily separated from inorganics by extracting with an immiscible solvent. Separation of organic mixtures can be possible if th ...
... The distribution/partition phenomenon is common and has been utilized to a great extent by various industrial and laboratory extraction processes. Organic compounds can be readily separated from inorganics by extracting with an immiscible solvent. Separation of organic mixtures can be possible if th ...
QUALITY BY DESIGN IN INHALATION PRODUCT DEVELOPMENT
... as QbD, is a buzzword not just in the pharma and other industries but also in design and development across a wide breadth of industries. The quality-by-design process builds quality in from the beginning of development and makes certain that this quality is maintained through statistical, analytica ...
... as QbD, is a buzzword not just in the pharma and other industries but also in design and development across a wide breadth of industries. The quality-by-design process builds quality in from the beginning of development and makes certain that this quality is maintained through statistical, analytica ...
STABILITY INDICATING HPTLC METHOD FOR SIMULTANEOUS DETERMINATION OF TELMISARTAN AND RAMIPRIL IN TABLETS
... standing blood pressure without significant alteration in the pulse rate. Ramipril is official in BP2 2007 and USP3 2007. Combinations of Telmisartan and Ramipril are available commercially as tablets in medicinally recommended ratios of 40:5 and 40:2.5 respectively. Telmisartan ...
... standing blood pressure without significant alteration in the pulse rate. Ramipril is official in BP2 2007 and USP3 2007. Combinations of Telmisartan and Ramipril are available commercially as tablets in medicinally recommended ratios of 40:5 and 40:2.5 respectively. Telmisartan ...
BAOJ Pharmaceutical Sciences
... permeability of drugs across the intestinal epithelium. Although several single chemical permeation enhancers have been shown to alleviate permeability difficulties, this often occurs at the expense of safety. The stratum corneum, oral mucosa and buccal mucosa pose a formidable challenge to formulat ...
... permeability of drugs across the intestinal epithelium. Although several single chemical permeation enhancers have been shown to alleviate permeability difficulties, this often occurs at the expense of safety. The stratum corneum, oral mucosa and buccal mucosa pose a formidable challenge to formulat ...
ENCLOSURE- I 6.1. BRIEF RESUME OF INTENDED WORK NEED
... tract (GIT) hence, incomplete and erratic absorption ultimately limits its clinical utility. Further, poorly soluble drugs are generally administered at much higher doses than the actual dose in order to achieve necessary drug plasma levels leading to increased adverse reaction & cost of therapy and ...
... tract (GIT) hence, incomplete and erratic absorption ultimately limits its clinical utility. Further, poorly soluble drugs are generally administered at much higher doses than the actual dose in order to achieve necessary drug plasma levels leading to increased adverse reaction & cost of therapy and ...
Module 1. General Clinical Pharmacy.Clinical Pharmacy in
... 33. What is the way of noradrenalin using? A. * Intravenous. B. Intramuscular. C. Per oral. D. Subcutaneous. E. Intracutaneous. 34. What is the effect of noradrenalin using? A. Vasodilating. B. * Vasoconstrictive. C. Bronchodilating. D. Bronchoconstrictive. E. Analeptic. 35. Angina pectoris is: A. * ...
... 33. What is the way of noradrenalin using? A. * Intravenous. B. Intramuscular. C. Per oral. D. Subcutaneous. E. Intracutaneous. 34. What is the effect of noradrenalin using? A. Vasodilating. B. * Vasoconstrictive. C. Bronchodilating. D. Bronchoconstrictive. E. Analeptic. 35. Angina pectoris is: A. * ...
Guidelines for Registration of Fixed
... 2.1.1 Many general guidelines are also applicable to FDCs. Table 1 lists some relevant WHO publications. 2.1.2 Other international guidelines that pertain to FDCs in particular are summarized in Table 2, together with brief notes as to their content. Some of these relate to particular therapeutic gr ...
... 2.1.1 Many general guidelines are also applicable to FDCs. Table 1 lists some relevant WHO publications. 2.1.2 Other international guidelines that pertain to FDCs in particular are summarized in Table 2, together with brief notes as to their content. Some of these relate to particular therapeutic gr ...